Definitive Healthcare Corp.

Definitive Healthcare Corp. (DH) Market Cap

Definitive Healthcare Corp. has a market capitalization of $72M.

Price: $0.68

-0.03 (-4.85%)

Market Cap: 72.00M

NASDAQ · time unavailable

CEO: Kevin D. Coop

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2021-09-15

Website: https://www.definitivehc.com

Definitive Healthcare Corp. (DH) - Company Information

Market Cap: 72.00M|Sector: Healthcare

Company Profile

Definitive Healthcare Corp. (DH), operating through its various subsidiaries, offers specialized commercial intelligence solutions for the U.S. healthcare industry. The company's services furnish essential data on healthcare providers and their activities, enabling clients to navigate critical business processes, from the early stages of product development to strategic market entry planning and effective sales and marketing execution. Its sophisticated platform incorporates sixteen distinct intelligence modules. These modules are designed to support key functional domains such as sales optimization, marketing initiatives, clinical research, new product creation, strategic planning, human capital acquisition, and the oversight of physician networks. Definitive Healthcare caters to a broad spectrum of clients, including biopharmaceutical firms, medical device manufacturers, healthcare information technology companies, and direct healthcare providers. Additionally, its clientele extends to diverse organizations within the wider healthcare ecosystem, such as staffing and commercial real estate companies, financial institutions, and other related entities. Founded in 2011, Definitive Healthcare Corp. is headquartered in Framingham, Massachusetts.

Analyst Sentiment

56%
Buy

From 9 Active Polls

1Y Forecast: $1.10

▲ +61.2% Potential Upside

Consensus Target Metrics

Low Bound

$1

Median

$1

High Bound

$1

Average

$1

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$1.10
▲ +61.22% Upside
Low Target
$1.10
61% Risk
Median Target
$1.10
61% Mid
High Target
$1.10
61% Max
Consensus
Hold
3 / 15 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)72129297421417326473520632
Enterprise Value ($M)84141306488514400620640772
Price to Earnings Ratio (P/E)-0.42-0.23-7.97-7.25-13.79-0.76-2.01-1.00-0.74
Price/Earnings-to-Growth Ratio (PEG)-3.22-5.24-1.83
Price to Sales Ratio (P/S)0.302.304.827.026.865.517.598.309.92
Price to Book Ratio (P/B)0.490.881.061.481.371.011.061.030.98
Price to Free Cash Flow Ratio (P/FCF)1.9415.40-172.4631.4324.4917.75-170.9027.8746.39
Enterprise Value to Sales (EV/Sales)2.524.978.138.456.779.9610.2012.11
Enterprise Value to EBITDA (EV/EBITDA)-0.48-0.78-59.70-2337.0560.28-2.67-8.39-3.46-2.48
Debt to Equity Ratio-0.071.160.610.620.590.560.570.510.40

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 DEFINITIVE HEALTHCARE CORP CLASS A (DH) — Investment Overview

🧩 Business Model Overview

Definitive Healthcare provides healthcare-focused data and software used to inform commercial planning, sales execution, and market strategy across the healthcare ecosystem. The platform aggregates and standardizes information on healthcare providers and healthcare organizations, enabling customers to segment accounts, validate affiliations, track ownership and practice structures, and identify opportunities for outreach.

The business is structured around distributing curated datasets and decision-support tools through subscription licenses. Customers typically embed the data into sales/marketing workflows and reporting processes, which increases operational dependency on the platform and makes ongoing subscription renewals a natural requirement for continued business execution.

💰 Revenue Streams & Monetisation Model

The monetisation model is primarily subscription-driven. Revenue is generated through:

  • Recurring data and platform subscriptions that provide access to curated datasets, search/browse functionality, and analytics workflows.
  • Usage- and module-based offerings that expand customer capability as teams require more coverage, enrichment, or specialized outputs.
  • Professional or implementation services when customers require onboarding, integration support, or customization of workflows.

Margin drivers follow typical high-value information software economics: gross margin strength supported by scalable data software distribution, with ongoing costs tied to data acquisition, standardization/quality assurance, and platform development. Commercial success is closely linked to retention and expansion within accounts as organizations broaden the number of teams and geographies using the platform.

🧠 Competitive Advantages & Market Positioning

Definitive Healthcare’s core moat is switching costs and data-driven operational dependency, supported by high barriers to entry in healthcare data curation.

  • High switching costs (workflow + data gravity): Customers build recurring segments, saved account views, and reporting structures around the platform. Moving to another provider requires re-mapping entities, re-validating relationships/affiliations, and re-establishing targeting logic—work that directly impacts sales productivity and accuracy.
  • Barriers to entry in healthcare data curation: The platform requires persistent collection, normalization, and validation of complex healthcare entity relationships (including practice and organizational structures). Competitors can offer overlapping data, but replicating breadth, consistency, and timeliness at scale is difficult and costly.
  • Integrated ecosystem advantage: The platform is designed for business users who need actionable targeting rather than raw records, which strengthens adoption across commercial and strategic teams.

Competitive benchmarking: Key competitors include IQVIA, Wolters Kluwer (health information and analytics), and Optum/UnitedHealth Group data and analytics offerings. These rivals often vary by end-market focus—ranging from broader healthcare analytics suites to provider-oriented or clinical-information solutions. Definitive Healthcare tends to position more directly around commercial-enablement and healthcare entity intelligence for sales and market strategy, rather than serving primarily as a clinical workflow system or a purely academic reference layer.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by structural demand for reliable healthcare intelligence:

  • Rising complexity in healthcare delivery: Continued consolidation, changing affiliations, and shifting care settings raise the value of continuously maintained provider and organization data.
  • Outsourced analytics for commercial execution: Pharmaceutical and health services organizations increasingly rely on specialized platforms to manage account targeting, segmentation, and go-to-market planning.
  • Expansion of use cases within existing accounts: As customers integrate the platform into more teams (sales, market access, strategy, and partnerships), the platform can deepen penetration.
  • Geographic and vertical adjacency: Opportunities exist to expand coverage breadth across provider types and related organizational categories where entity resolution and relationship mapping are valuable.
  • Data accuracy and compliance as a differentiator: Customers prefer vendors that reduce operational risk by maintaining high-quality entity matching and robust sourcing.

⚠ Risk Factors to Monitor

  • Data quality and entity resolution risk: The platform’s value depends on accuracy, coverage, and timeliness. Errors or data gaps can reduce customer trust and increase churn risk.
  • Regulatory and privacy constraints: Healthcare-related data activities must align with applicable privacy rules and licensing/source agreements. Compliance failures can increase operating restrictions and costs.
  • Competitive pressure from larger analytics suites: Major firms can bundle datasets and analytics across broader portfolios, potentially influencing customer purchasing decisions.
  • Customer concentration and procurement dynamics: Enterprise customers can negotiate renewals aggressively, particularly if internal stakeholders view alternative solutions as interchangeable.
  • Cybersecurity and operational resilience: As a data-centric platform, robust security controls and uptime are critical to sustaining enterprise adoption.

📊 Valuation & Market View

Equity markets typically value healthcare data and software companies using SaaS-relevant frameworks such as EV/Revenue, EV/ARR, and—where profitability is visible—EV/EBITDA. The key valuation drivers tend to be:

  • Recurring revenue quality: retention, renewal durability, and account expansion.
  • Unit economics: gross margin stability and cost discipline tied to data acquisition and platform scale.
  • Growth durability: sustainable demand for healthcare entity intelligence, not solely one-time budget cycles.
  • Operating leverage path: ability to convert revenue growth into operating income as platform and data infrastructure scale.

In this sector, valuation sensitivity generally increases when investors perceive either (i) durable switching costs and sticky usage, or (ii) improving margin structure through scaling efficiencies and reduced marginal delivery cost.

🔍 Investment Takeaway

Definitive Healthcare has a durable long-term positioning built on switching costs, healthcare data curation barriers, and workflow-integrated intelligence. The company benefits from secular demand for high-quality healthcare entity data amid rising delivery complexity and continued outsourcing of commercial analytics. The investment case centers on sustaining customer retention, expanding account penetration through additional modules and use cases, and maintaining data quality and sourcing credibility against well-resourced analytics competitors.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for DH.

zacks.com2026-07-30

Analysts Estimate Definitive Healthcare Corp. (DH) to Report a Decline in Earnings: What to Look Out for

Definitive Healthcare (DH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

globenewswire.com2026-07-27

Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

FRAMINGHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Srinivas Attipalli of the Company, Definitive Healthcare's new SVP and Head of AI & Data - Product, an inducement award consisting of 1,063,830 time-based restricted stock units (“RSUs”), effective July 24, 2026. These awards were individually negotiated and granted as an inducement material to Mr. Attipalli's respective commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

prnewswire.com2026-06-23

Restaurant365 Names Kate Hastings Chief Customer Officer as It Expands Investment in Customer Success

Customer success leader joins executive team to help restaurant operators accelerate value realization, adoption, and business outcomes. IRVINE, Calif.

globenewswire.com2026-05-21

Definitive Healthcare advances data platform and integrations to deliver smarter healthcare insights

FRAMINGHAM, Mass. , May 21, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), a provider of healthcare data and analytics, today announced several product enhancements designed to give organizations a clearer view of the healthcare ecosystem and help them act on critical market intelligence faster.

globenewswire.com2026-05-21

Definitive Healthcare advances data platform and integrations to deliver smarter healthcare insights

Latest enhancements provide deeper medical claims insights, a new integration with HubSpot®, seamless access to healthcare professional (HCP) data directly in Salesforce, and AI search capabilities Latest enhancements provide deeper medical claims insights, a new integration with HubSpot®, seamless access to healthcare professional (HCP) data directly in Salesforce, and AI search capabilities

seekingalpha.com2026-05-08

Definitive Healthcare Corp. (DH) Q1 2026 Earnings Call Transcript

Definitive Healthcare Corp. (DH) Q1 2026 Earnings Call Transcript

zacks.com2026-05-07

Definitive Healthcare Corp. (DH) Tops Q1 Earnings Estimates

Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.05 per share a year ago.

globenewswire.com2026-05-07

Definitive Healthcare Reports Financial Results for First Quarter 2026

FRAMINGHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced financial results for the quarter ended March 31, 2026.

zacks.com2026-04-30

Analysts Estimate Definitive Healthcare Corp. (DH) to Report a Decline in Earnings: What to Look Out for

Definitive Healthcare (DH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

globenewswire.com2026-04-23

Definitive Healthcare Announces Timing of Its First Quarter 2026 Financial Results Conference Call and Webcast

FRAMINGHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that it will report financial results for its first quarter ended March 31, 2026, on Thursday, May 7, 2026 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.

seekingalpha.com2026-02-27

Definitive Healthcare Corp. (DH) Q4 2025 Earnings Call Transcript

Definitive Healthcare Corp. (DH) Q4 2025 Earnings Call Transcript

defenseworld.net2026-02-27

Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of “Hold” by Brokerages

Definitive Healthcare Corp. (NASDAQ: DH - Get Free Report) has earned an average recommendation of "Hold" from the eight ratings firms that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, one has issued a buy recommendation and one has assigned a strong

zacks.com2026-02-26

Definitive Healthcare Corp. (DH) Matches Q4 Earnings Estimates

Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.08 per share a year ago.

globenewswire.com2026-02-26

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025

FRAMINGHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced financial results for the quarter and full year ended December 31, 2025.

defenseworld.net2026-02-19

Definitive Healthcare (DH) Projected to Post Quarterly Earnings on Thursday

Definitive Healthcare (NASDAQ: DH - Get Free Report) will likely be issuing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $59.5660 million for the quarter. Interested persons can check the company's upcoming Q4 2025 earning summary page for

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"DH reported Q1 2026 revenue of $55.9M and net loss of $138.6M (EPS -$1.32). Compared with Q4 2025, revenue declined (-9.1% QoQ from $61.5M to $55.9M), while net loss widened materially (net loss of $138.6M vs net loss of $9.3M in Q4). On a YoY basis, revenue decreased slightly (-5.5% vs $59.2M in Q1 2025), and net loss increased substantially (loss -$138.6M vs -$107.2M), indicating worsening profitability. Margins deteriorated across the quarter: gross margin improved (74.5% vs 68.1% in Q4), but operating and net margins stayed deeply negative and worsened versus Q4 (operating margin -360% vs +2.9% in Q4; net margin -248% vs -15%). This points to significant volatility largely driven by “other expenses” (notably large in Q1 2026). Cash flow remained positive on an operating basis: operating cash flow was $11.6M and free cash flow was $8.4M, even as net income stayed highly negative. Balance sheet resilience appears solid with $178.1M cash & short-term investments and very low net debt (-$150.5M). There were no dividends paid; buybacks/financing were also not evident in Q1. Total shareholder returns likely remain weak given the stock’s sharp 1-year decline (-59.3%)."

Revenue Growth

Neutral

Revenue fell -9.1% QoQ (from $61.5M to $55.9M) and -5.5% YoY (from $59.2M). No clear improving trajectory.

Profitability

Neutral

Despite gross margin improving (74.5% vs 68.1% QoQ), net margin deteriorated sharply to -2.48x and EPS worsened to -$1.32. YoY net loss increased (to -$138.6M from -$107.2M).

Cash Flow Quality

Caution

Operating cash flow was positive at $11.6M and free cash flow $8.4M in Q1. However, this is not supported by net income, which remains deeply negative.

Leverage & Balance Sheet

Positive

Liquidity remains strong (cash & ST investments $178.1M) and net debt is negative (-$150.5M), implying low balance-sheet risk. Equity remains positive (~$190.7M).

Shareholder Returns

Neutral

No dividend. Q1 cash flow did not show meaningful buybacks; market performance is weak with 1y_change of -59.3%.

Analyst Sentiment & Valuation

Neutral

Price is $1.03 while consensus target is $3.13, suggesting upside in valuation expectations, but profitability deterioration and volatility temper the score.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Definitive Healthcare delivered a strong margin and cash-flow quarter despite ongoing top-line contraction. Q1 revenue was $55.9M (-6% YoY) but exceeded the guidance high-end, with adjusted EBITDA of $15.3M producing a 27% margin and ~260 bps of YoY expansion—driven by expense discipline plus favorable timing/cost classification effects. Life Sciences remains the key drag, attributed to lingering claims disruption and a biopharma macro shift toward earlier-stage R&D; management frames the claims issue as largely repaired and suggests the worst of downsell pressure is behind them as claims data returns to historical levels. On the growth side, management highlighted a record win-back quarter and continued momentum in Diversified/Provider, supported by data differentiation, faster integrations, and early-stage AI plans to launch later this quarter. Integrations are scaling quickly (avg days ~45 in Q1; nearly 50 new integrations), with new HubSpot and enhanced Salesforce connectivity intended to improve retention and renewal stickiness. Outlook implies continued revenue declines in Q2 and FY, but margin expectations remain resilient.

AI IconGrowth Catalysts

  • Fall expansion pack release improved breadth/quality of claims data; cited overwhelmingly positive feedback.
  • Highest win-back quarter in over 3 years; several 6-figure win-backs in diversified/med tech attributed to data breadth/quality and service trust.
  • AI-enabled acceleration planned: first AI-enabled solutions expected to launch later in Q1/Q2 timeframe (“later this quarter”), starting with a natural-language, AI-driven interface embedded in the existing platform.
  • Digital activation progress: 30+ agencies signed up, with more than half actively generating bookings; click-through rate benchmarked at 63% higher vs a leading competitor.

Business Development

  • HubSpot integration introduced in Q1 to access Definitive reference/affiliation/financial/clinical data directly inside HubSpot CRM.
  • Salesforce integration enhancements added in Q4 to bring healthcare provider data directly into customers’ Salesforce instances (physician identification/segmentation/engagement).
  • Upsell win: biopharma customer using Monocl (existing Monocl user, upsold following acquisition by a larger organization).
  • Life sciences win: 6-figure multiyear win with a life sciences customer previously using a generic multi-vertical data source (oncology/rheumatology focus; improved KOL identification and sales targeting).

AI IconFinancial Highlights

  • Revenue: $55.9M, down 6% YoY; at the upper end of guidance range.
  • Adjusted EBITDA: $15.3M, 27% margin; expanded ~260 bps YoY and was $2.3M above the high end of guidance.
  • Adjusted net income: $8.5M; non-GAAP EPS $0.06 (at/above guidance high end).
  • Gross profit: adjusted gross profit $45.2M; adjusted gross margin expanded nearly 150 bps YoY (81%) driven by short-term gap between removing one data source and onboarding another.
  • Subscription revenue: $53.6M, down 7% YoY; “about 2 points” benefit from data partnership timing in Q1, fully wrapping in Q2.
  • Professional services revenue up 25% YoY, attributed to traditional analytics engagement and ramp in digital activations.
  • Cash flow: $18M unlevered free cash flow in Q1; nearly $50M unlevered FCF for trailing 12 months; conversion 70% of trailing 12-month adjusted EBITDA to unlevered FCF (down ~20 points YoY).
  • Accounting: goodwill impairment of $197M as of March 31 (noncash); remeasurement gain on TRA liability $6.6M and deferred tax benefit $3.6M (noncash).

AI IconCapital Funding

  • No buyback authorization/amount disclosed in the provided transcript.
  • Debt/cash runway not quantified in the provided transcript.
  • Capex/Cash neutral classification shift: higher capitalized software development spend; shifting costs from R&D to CapEx described as cash neutral.

AI IconStrategy & Ops

  • Integrations: completed nearly 50 new integrations in Q1; reduced time to integrate by nearly 50% YoY.
  • Integration speed/velocity metrics: average days for integration improved from 73 days in Q4 to ~45 days in Q1; “75% more integrations” over the last 6 months vs prior 6 months (before that).
  • AI packaging/product strategy: embedding an AI-driven, natural-language query interface in the existing platform to democratize access and improve value/retention; monetization expected to evolve from retention/renewal value to pricing power as features expand.
  • Digital engagement: more than 30 agencies signed up; active booking generation >1/3 last quarter to >1/2 currently; scaling planned “later this year in 2026 and beyond.”

AI IconMarket Outlook

  • Q2 2026 guidance: total revenue $55M to $56M (-8% to -9% YoY).
  • Q2 adjusted EBITDA: $13.5M to $14.5M (24% to 26% margin).
  • Q2 adjusted net income: $5M to $6M; EPS approx. $0.03 to $0.04 (diluted share count 144.2M).
  • Full-year 2026 guidance: revenue $220M to $226M (-6% to -9% YoY).
  • Full-year 2026 adjusted EBITDA: $55M to $59M (25% to 26% margin).
  • Full-year 2026 adjusted operating income: $43.5M to $47.5M (midpoint increased by $1.5M).
  • Full-year 2026 adjusted net income: $23M to $27M; EPS $0.16 to $0.19 (144.9M weighted avg shares).

AI IconRisks & Headwinds

  • Life sciences continued decline driven by “claims disruption” and a challenging macro environment; management indicated slower response in Life Sciences vs Diversified/Provider.
  • RPO declines: remaining performance obligations declined 18% YoY overall; current RPO $161M (-12% YoY); explained by shift toward single-year deals vs multiyear commitments (including cRPO impact).
  • Cash conversion pressure: trailing 12-month adjusted EBITDA to unlevered FCF conversion down ~20 points YoY due to unique prior-year items.
  • Macro-biopharma spending mix: larger biopharma shifting dollars from commercialization to earlier-stage R&D, muting second-stage commercialization demand.
  • Guidance implies continued YoY revenue pressure (Q2 -8% to -9%; FY -6% to -9%).

Q&A: Analyst Interest

  • Life Sciences timing: “when claims disruption will stop being a factor” and whether renewal/downsell pressure is over. Management tied the headwind to claims data payload declines, said Q1 is at/above historical claims levels, expects improved renewal down pressure, but acknowledged buying decisions occur earlier than remediation.
  • Integration maturity and speed: analyst asked whether HubSpot/Salesforce work is through low-hanging fruit or in later stages. Management cited integration day reduction from 100+ to 73 days in Q4 and ~45 days in Q1, plus 75% more integrations over the last 6 months, and described HubSpot as “productizing” access inside CRM.
  • AI monetization mechanics: analyst asked whether AI is retention-only or an incremental SKU/pricing lever. Management said democratization via AI should first improve retention and increase value in an existing value-based licensing model; later, additional feature functionality could create more pricing power as upsell opportunities expand.

Sentiment: MIXED

Note: This summary was synthesized by AI from the DH Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for DH.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (DH)

© 2026 Stock Market Info — Definitive Healthcare Corp. (DH) Financial Profile